Register Here

Agenda

  • 7:45 am

  • Registration & Coffee/Tea

    Chaired by:


    Aiman Shalabi, PharmD

    VP R&D, Cell and Gene Therapies, GSK

  • 8:15 am

  • IO360˚ Opening Remarks


    Andrew Baum, MD

    Head of Global Healthcare; Managing Director, Equity Research, Citi


    Ian McCaffery, PhD

    VP, Oncology Translational Science, Janssen R&D

  • 8:25 am

  • Opening Keynote: Lighting the Fire of Biotech Innovation


    Arie Belldegrun, MD, FACS

    Executive Chairman & Co-founder, Allogene

  • 8:50 am

  • Financial Keynote: Evaluation and Forecast of the IO Space


    Andrew Baum, MD

    Head of Global Healthcare; Managing Director, Equity Research, Citi

  • 9:15 am

  • Opening of the Exhibit & Networking Café, Breakfast & Partnering Meetings

  • 9:55 am

  • Landscape and Evolution of the Cell & Gene Therapy Marketplace

    Led by:

    Brad Loncor
    Brad Loncar

    CEO, Loncar Investments

    Participants:

    Amanda Murphy
    Amanda Murphy

    Managing Director, Biotechnology Research, BTIG

    Vanessa Lucey
    Vanessa Lucey, PhD

    Director, CRI Venture Fund and Clinical Accelerator, Cancer Research Institute

    Janet Lambert
    Janet Lynch Lambert

    CEO, Alliance for Regenerative Medicine


    Adrian McKemey, PhD

    Managing Director and Head of R&D Strategy Solutions, IQVIA

  • 10:40 am

  • Innovation Hour: New Scientific Frontiers in Cell Therapies for Solid Tumors

    Led by:

    Crystal Mackall
    Crystal Mackall, MD

    Professor of Pediatrics and Medicine; Director, Stanford Center for Cancer Cell Therapy; Director, Parker Institute for Cancer Immunotherapy at Stanford; Associate Director, Stanford Cancer Institute, Stanford University School of Medicine

    Participants:

    Azam
    Usman “Oz” Azam, MD

    President & CEO, Tmunity

    Cheng Liu
    Cheng Liu, PhD

    Founder & CEO, Eureka Therapeutics


  • Cell Therapy Pivotal Pharma Developments for Solid Tumors

  • 11:40 am

  • TILS Targeting Individual Tumor Mutations

    Stephanie Goff
    Stephanie Goff, MD

    Associate Research Physician, Surgery Branch, National Cancer Institute, NIH

  • 12:00 pm

  • Investigating the Power of Tumor Infiltrating Lymphocytes for Treatment of Cancer


    Maria Fardis, PhD

    President and CEO, IOVANCE Biotherapeutics

  • 12:15 pm

  • Update on NY-ESO


    Aiman Shalabi, PharmD

    VP R&D, Cell and Gene Therapies, GSK

  • 12:35 pm

  • Lunch & Partnering Meetings

  • 1:30 pm

  • Virus Specific T Cells as Platform for Solid Tumor Immunotherapy

    The ability to simultaneously monitor changes in multiple immune parameters holds great discriminatory and instructive power for the purpose of biomarker validation and mechanistic target discovery. In the case of Virus Specific T cell therapy for solid tumors, an examination of the systemic, cellular and local immune environment during the course of treatment has yielded a series of predictive biomarkers correlating with immunogenicity, response to therapy and overall survival on trial.  An analysis of antigen specific T-cells have identified anti-viral responses with positive prognostic value. Differences in the immunosuppressive state of the patient’s activated regulatory T-cells (Tregs) and the expansion or contraction of the myeloid-derived suppressor cell (MDSC) compartment, point to a mechanism of action for the therapy.


    John Connolly, PhD

    Chief Scientific Officer, Tessa Therapeutics Ltd

  • 1:50 pm

  • Evidence-based Accelerators for Early Phase IO Clinical Development

    How can you use innovation and calculated risk to accelerate development of cell therapies?  In this talk, IQVIA discusses modeling of IO data to develop new types of strategies vs. modeling strategies to develop new types of evidence.  Lessons learned from early cell therapy entrants on finding, recruiting and following the ‘right’ patients will also be presented.


    Chris Learn, PhD

    Senior Therapeutics Strategy Director, Cell and Gene Therapy, IQVIA

  • 2:05 pm

  • Current and Future Innovations Toward GMP Manufacturing of CAR and TCR Engineered T cells

    Paglia_Michael
    Michael Paglia

    VP, CMC Operations, ElevateBio

  • 2:25 pm

  • High Throughput Identification of Naturally-Occurring TCRs for Cellular Therapeutics

    Sharon Benzeno
    Sharon Benzeno, PhD

    SVP, Drug Discovery, Adaptive Biotechnologies

  • 2:40 pm

  • Panel: Evolution of Regulatory Policy For Cell/Gene Therapy

    Moderator:

    Peter Marks
    Peter Marks, MD, PhD

    Director, Center for Biologics Evaluation and Research (CBER), FDA

    Panelists:


    Jeff Allen, PhD

    President & CEO, Friends of Cancer Research

    Anne Chew
    Anne Chew, PhD

    Executive Deputy Director, Center for Cellular Immunotherapies, University of Pennsylvania

    Additional Panelists TBD

  • 3:25 pm

  • Afternoon Networking Break & Partnering Meetings


  • Moving Beyond Pharma: New Collaborative Development Paradigms for Cell Therapies

  • 4:05 pm

  • Master Protocol for Cell/ Gene Therapies and Parker Institutes Efforts/Innovations in Cell Therapy


    Ramy Ibrahim, MD

    Chief Medical Officer and VP, Clinical Development, Parker Institute for Cancer Immunotherapy

  • 4:15 pm

  • Unlocking Trapped Innovation in Cell, Gene Therapy & Regenerative Medicine

    Finer_Mitch
    Mitch Finer, PhD

    CSO, President and Executive Partner, ElevateBio

  • 4:25 pm

  • Cancer Therapy Evaluation Program Innovations in Cell Therapy (CTEP)

    Sharon_Elad
    Elad Sharon, MD

    Senior Investigator, Cancer Therapy Evaluation Program (CTEP), National Cancer Institute

  • 4:35 pm

  • Canadian Cancer Trials Group (CCTG)

    Speaker TBD

  • 4:45 pm

  • Panel: New Collaborative Development Paradigms for Cell Therapies

    Led by:


    Ramy Ibrahim, MD

    Chief Medical Officer and VP, Clinical Development, Parker Institute for Cancer Immunotherapy

    Panelists:

    Finer_Mitch
    Mitch Finer, PhD

    CSO, President and Executive Partner, ElevateBio

    Sharon_Elad
    Elad Sharon, MD

    Senior Investigator, Cancer Therapy Evaluation Program (CTEP), National Cancer Institute


  • Cell & Gene Therapy Debates

  • 5:15 pm

  • Combinations with Checkpoints

    Moderated by:


    Ramy Ibrahim, MD

    Chief Medical Officer and VP, Clinical Development, Parker Institute for Cancer Immunotherapy

    with

    Priceman
    Saul Priceman, PhD

    Assistant Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope

    vs

    Mark O'Hara
    Mark O’Hara, MD

    Assistant Professor of Medicine, University of Pennsylvania

  • 5:35 pm
    - 5:55 pm

  • Bedside Manufacturing vs Centralized Manufacturing


    Boro Dropulić, PhD

    Chief Science Officer & General Manager, Lentigen

    vs

    Patrick Hanley
    Patrick Hanley, PhD

    Director, GMP for Immunotherapy / Associate Professor, Children’s National Medical Center / George Washington University

  • 6:00 pm

  • Networking Reception